- $8.80bn
- $7.81bn
- $579.91m
2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 81.2 | 152 | 253 | 424 | 580 |
Cost of Revenue | |||||
Gross Profit | 71.9 | 134 | 223 | 373 | 521 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 210 | 366 | 382 | 618 | 776 |
Operating Profit | -128 | -214 | -129 | -194 | -196 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -130 | -189 | -159 | -178 | -164 |
Provision for Income Taxes | |||||
Net Income After Taxes | -131 | -192 | -158 | -181 | -428 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -131 | -192 | -155 | -172 | -424 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -131 | -192 | -155 | -172 | -424 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.914 | -1.34 | -1.95 | -1.24 | -2.67 |
Dividends per Share |